Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

BofA notes that AstraZeneca (AZN) shares are down greater than 10% in the last few days on the back of China concerns around the ongoing ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance ...

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

AstraZeneca shares fell 8% in London Tuesday, the biggest drop in four years following a fresh report that a Chinese investigation of the company has widened. AstraZeneca said last week that its China ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge fall? The post The AstraZeneca share price just fell 8.4% in a day. Is it ...

Astra saw £14.4bn wiped off its value after Chinese media said dozens of managers were implicated in a scandal.